[Clinical trial of UFT in recurrent or advanced cancer].
Gan To Kagaku Ryoho
; 9(1): 72-8, 1982 Jan.
Article
em Ja
| MEDLINE
| ID: mdl-6820878
ABSTRACT
UFT, antitumor agent containing uracil and futraful (FT-207), was given orally to 14 patients with recurrent or advanced carcinomas (6 gastric, 5 colorectal and 3 other carcinomas) and the clinical effects were evaluated. One PR (partial response) 1 NC (no change) and 9 PD(progressive disease) were obtained among 11 evaluable patients. Response rate was 9.1% (1/11), and overall response rate was 14.3% (2/14). According to Karnofsky's criteria, 2 responders (better than I-A) were obtained and response rate was 15.4% (2/13).
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Uracila
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tegafur
/
Fluoruracila
/
Antineoplásicos
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
1982
Tipo de documento:
Article